Literature DB >> 22522983

Differences in sensitivity to rocuronium among orbicularis oris muscles innervated by normal or damaged facial nerves and gastrocnemius muscle innervated by somatic nerve in rats: combined morphological and functional analyses.

Ru-Yuan Zhou1, Jing Xu, Fang-Lu Chi, Lian-Hua Chen, Shi-Tong Li.   

Abstract

OBJECTIVES/HYPOTHESIS: To evaluate mechanisms of discrepant responses to the nondepolarizing muscle relaxant rocuronium among normal and injured facial nerve-innervated orbicularis oris and tibial nerve-innervated gastrocnemius, and to provide information for the proper use of muscle relaxants to balance evoked electromyography (EEMG) monitoring and immobility in general anesthesia. STUDY
DESIGN: Randomized controlled study.
METHODS: Right-sided facial nerve injury was induced by crush axotomy in 18 Sprague-Dawley rats. At different rocuronium concentrations, muscular tension amplitude (MTA) was determined in vitro for normal and injured facial nerve-innervated orbicularis oris and gastrocnemius; the number of unsaturated acetylcholine receptors (AChRs) at end plates was determined by (125) I-α-bungarotoxin staining followed with gamma spectroscopy. The morphological composition of muscle fibers was determined by histological examination.
RESULTS: Following rocuronium incubation, the percentage of MTA inhibition (MTAI%) of gastrocnemius was significantly higher than the corresponding values of orbicularis oris (P < .05), and the degree of saturation of AChR in gastrocnemius was significantly greater than that in orbicularis oris (P < .05). The baseline MTA and AChR density of injured-side orbicularis oris was significantly smaller than those of the normal side, whereas no significant difference was found regarding MTAI% and the degree of AChR saturation between the normal and injured side.
CONCLUSIONS: The affinity of AChR at end plates and different number of AChR per unit fiber cross-sectional area may be the mechanisms for differential sensitivities to neuromuscular blockers between facial nerve-innervated muscles and somatic nerve-innervated muscles. The lower EEMG responses in the impaired facial nerve-innervated muscles may result from the lower AChR density at end plates compared with the normal facial nerve-innervated muscles.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522983     DOI: 10.1002/lary.23286

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Facial nerve axotomy in mice: a model to study motoneuron response to injury.

Authors:  Deborah N Olmstead; Nichole A Mesnard-Hoaglin; Richard J Batka; Melissa M Haulcomb; Whitney M Miller; Kathryn J Jones
Journal:  J Vis Exp       Date:  2015-02-23       Impact factor: 1.355

2.  Effect of rocuronium on the level and mode of pre-synaptic acetylcholine release by facial and somatic nerves, and changes following facial nerve injury in rabbits.

Authors:  Jinghua Tan; Jing Xu; Yian Xing; Lianhua Chen; Shitong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Effect of electroacupuncture on the expression of agrin and acetylcholine receptor subtypes in rats with tibialis anterior muscular atrophy induced by sciatic nerve injection injury.

Authors:  Jianqi Yu; Meng Wang; Junying Liu; Xiaoming Zhang; Shengbo Yang
Journal:  Acupunct Med       Date:  2017-01-09       Impact factor: 2.267

4.  Differences in pharmacodynamic responses to rocuronium in normal or injured orbicularis oris are associated with expression of acetylcholine receptor subunits.

Authors:  Yong Huang; Yian Xing; Hong Wang; Lianhua Chen; Shitong Li
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

5.  Inhibiting Matrix Metalloproteinases Protects Evoked Electromyography Amplitudes and Muscle Tension in the Orbicularis Oris Muscle in a Rat Model of Facial Nerve Injury.

Authors:  Shuang Wu; Lijun Song; Meirong Yu; Chao Gong; Lianhua Chen
Journal:  J Neuropathol Exp Neurol       Date:  2022-09-19       Impact factor: 3.148

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.